Benzgalantamine

ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.
Do not take if: ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredient in ZUNVEYL.
Serious skin reactions have occurred.

Side effects, and when to stop

The following serious adverse reactions are discussed in more detail elsewhere in the labeling:

Serious Skin Reactions
Cardiovascular Conditions
Gastrointestinal Conditions
Genitourinary Conditions
Neurological Conditions
Pulmonary Conditions

Who should not take it

ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredient in ZUNVEYL. Serious skin reactions have occurred.

Storing it

Store ZUNVEYL delayed-release tablets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Benzgalantamine; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/benzgalantamine
APA 7th: sofidex. (2026, August 2). Benzgalantamine. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/benzgalantamine
AMA 11th: Benzgalantamine. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/benzgalantamine

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.